cancer
wildpixel / iStockphoto.com
23 March 2018Americas

Novartis partners with Harvard on biomaterial systems

Novartis and Harvard University have teamed up to develop Harvard’s proprietary biomaterial systems to deliver cancer immunotherapies.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
17 April 2026   A ruling that invalidated three of Teva's headache treatment patents has been thrown out, sending a long-running case back to the lower court.
Americas
16 April 2026   The Cambridge biotech is accused of infringing six patents covering technologies used to target drug-resistant cancer mutations.
Americas
14 April 2026   A US district court has allowed key elements of the generic drugmaker’s case against a rival to move forward, while drawing clear limits on how far the complaint can reach.